Ionis Pharmaceuticals
Biotechnology company
Follow Ionis Pharmaceuticals on Notably News to receive short updates to your email — rarely!
| December 2024 | Ionis Pharmaceuticals secured FDA approval for Tryngolza (olezarsen), a treatment for familial chylomicronemia syndrome, marking its first independent drug launch in 35 years. |
| December 2016 | Nusinersen (Spinraza) received FDA approval, developed in collaboration with Adrian Krainer from Cold Spring Harbor Laboratory. |
| January 2016 | Ionis terminated its arrangement with Genzyme regarding mipomersen, citing poor marketing. |
| 2013 | Mipomersen (Kynamro) received FDA approval for treating homozygous familial hypercholesterolemia. |
This contents of the box above is based on material from the Wikipedia article Ionis Pharmaceuticals, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.